Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia

References

• Ministry of Health, Malaysia. Malaysia National Cancer Registry report 2012–2016; 2019.
   Google Scholar
• Ministry of Health, Malaysia. Malaysian study on cancer survival (MySCan); 2018.
   Google Scholar
• Kan CS, Chan KM. A review of lung cancer research in Malaysia. Med J Malaysia. 2016;71(Suppl 1):70–78.
   PubMedGoogle Scholar
• Shi Yeen TN, Pathmanathan R, Shiran MS, Ahmad Zaid FA, Cheah YK. Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. J Biomed Sci. 2013;20(1):22.
   PubMed Web of Science ®Google Scholar
• Werutsky G, Debiasi M, Sampaio FH, et al. P1.08: updated analysis of global epidemiology of EGFR Mutation in advanced non-small cell lung cancer: track: prevention, early detection, epidemiology and tobacco control. J Thorac Oncol. 2016;11(10):S184–S185. doi:10.1016/j.jtho.2016.08.030
   Web of Science ®Google Scholar
• Liam CK, Leow HR, How SH, et al. Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population. Asian Pac J Cancer Prev. 2014;15(1):321–326. doi:10.7314/APJCP.2014.15.1.321
   PubMedGoogle Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up††footnotes approved by the ESMO Guidelines Committee: February 2002, last update September 2018. Ann Oncol. 2016;27(Suppl 5):v1–v27.
   PubMedGoogle Scholar
• Ho G-F, Chai C-S, Alip A, et al. Real-world experience of first-line Afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 2019;19(1):896. doi:10.1186/s12885-019-6107-1
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 2010;11(2):121–128. doi:10.1016/S1470-2045(09)70364-X
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X
   PubMed Web of Science ®Google Scholar
• Lavacchi D, Mazzoni F, Giaccone G. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Drug Des Devel Ther. 2019;13:3187–3198. doi:10.2147/DDDT.S194231
   PubMed Web of Science ®Google Scholar
• Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011;3(1):10–18. doi:10.3978/j.issn.2072-1439.2010.12.02
   PubMedGoogle Scholar
• Wu S-G, Chiang C-L, Liu C-Y, et al. An observational study of acquired EGFR T790M-dependent resistance to EGFR-TKI treatment in lung adenocarcinoma patients in Taiwan. Front Oncol. 2020;10:1481. doi:10.3389/fonc.2020.01481
   PubMed Web of Science ®Google Scholar
• Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. doi:10.1186/s12943-018-0777-1
   PubMed Web of Science ®Google Scholar
• Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–1296. doi:10.1200/JCO.2016.70.3223
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-2246
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Carbonnaux M, Souquet P-J, Meert A-P, Scherpereel A, Peters M, Couraud S. Inequalities in lung cancer: a world of EGFR. Eur Respir J. 2016;47(5):1502–1509. doi:10.1183/13993003.01157-2015
   PubMed Web of Science ®Google Scholar
• Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568–577. doi:10.1097/JTO.0b013e3181a0d82e
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Dwan K, Boland A, et al.First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;(5):Cd010383. doi:10.1002/14651858.CD010383.pub2
   PubMed Web of Science ®Google Scholar
• Chua B, Tan EH, Lim DWT, et al. Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. Ann Oncol. 2018;29:ix161. doi:10.1093/annonc/mdy425.033
   Web of Science ®Google Scholar
• Tu C, Chen C, Hsia T, Liao W, Chen W, Hsu W. P1.03-053 Taiwan real word efficacy of 1st line EGFR TKIs treatment in EGFR mutation positive advanced non-small cell lung cancer. J Thorac Oncol. 2017;12(11):S1971. doi:10.1016/j.jtho.2017.09.858
   Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2017;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Hochmair M, Schwab S, Burghuber O, et al. P2.03-025 prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib. J Thorac Oncol. 2017;12(11):S2137. doi:10.1016/j.jtho.2017.09.1276
   Web of Science ®Google Scholar
• Okamoto I, Morita S, Tashiro N, et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort. Lung Cancer. 2018;117:14–19. doi:10.1016/j.lungcan.2018.01.005
   PubMed Web of Science ®Google Scholar
• Jovanovic D, Stevic R, Velinovic M, et al. Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. Onco Targets Ther. 2017;10:4347–4354. doi:10.2147/OTT.S131756
   PubMed Web of Science ®Google Scholar
• Nishii Y, Hataji O, Ito K, et al. Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status. Mol Clin Oncol. 2018;8(2):246–249. doi:10.3892/mco.2017.1522
   PubMed Web of Science ®Google Scholar
• Seto T, Nogami N, Yamamoto N, et al. Real-world EGFR T790M testing in advanced non-small-cell lung cancer: a prospective observational study in Japan. Oncol Ther. 2018;6(2):203–215. doi:10.1007/s40487-018-0064-8
   PubMed Web of Science ®Google Scholar
• Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 2020;20(1):356. doi:10.1186/s12885-020-06826-0
   PubMed Web of Science ®Google Scholar
• So YJ, Fraser A, Rivalland G, McKeage M, Sullivan R, Cameron L. Osimertinib in NSCLC: real-world data from New Zealand. JTO Clin Res Rep. 2020;1(2):100022. doi:10.1016/j.jtocrr.2020.100022
   PubMedGoogle Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504–535. doi:10.6004/jnccn.2017.0050
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J Clin Oncol. 2020;38(2):115–123. doi:10.1200/JCO.19.01488
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR -mutated lung cancer. J Clin Oncol. 2020;38(2):124–136. doi:10.1200/JCO.19.01154
   PubMed Web of Science ®Google Scholar